News
May 23, 2017 – Results now published in the European Heart Journal show Biotronik Home Monitoring reduces the risk of ...
May 24, 2017
News
W. L. Gore & Associates (Gore) announced positive results from its REDUCE Study assessing closure of patent foramen ovale (PFO) for the reduction of recurrent ischemic stroke and new brain infarct. The data were shared May 16 at the European Stroke Organisation Conference (ESOC) in Prague, Czech Republic. Gore plans to submit the positive data to the U.S. Food and Drug Administration (FDA) to seek a PFO indication for the Gore Cardioform Septal Occluder by year-end 2017.
May 24, 2017
News | Cardiovascular Ultrasound
May 24, 2017 — Philips recently announced the results from a global study indicating that automated three-dimensional ...
May 24, 2017Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
News | Heart Failure
Death in patients with heart failure is inversely related to the wealth of the country they live in, according to late breaking results from the INTERCHF study presented at Heart Failure 2017 and the 4th World Congress on Acute Heart Failure, April 29-May 2 in Paris, France. Death rates in India and Africa were three to four times higher than those documented in Western countries.
May 24, 2017
News | Cardiovascular Ultrasound
May 23, 2017 — The American Society of Echocardiography (ASE) will host its 28th Annual Scientific Sessions, June 2-6 ...
May 23, 2017
News | Cath Lab
Shockwave Medical announced last week CE Mark for the company’s Coronary Lithoplasty System for the treatment of calcified plaque in conjunction with stenting in patients with coronary artery disease.
May 23, 2017Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
Feature
May 23, 2017 — Diagnostic and Interventional Cardiology (DAIC) won the 2017 Azbee National Bronze Award and the Regional ...
May 23, 2017
News | Endovascular Aortic Repair
Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and branched-graft devices, based on a report of prospectively studied patients with complex aortic aneurysm in the May edition of the Journal of Vascular Surgery.
May 23, 2017
News | Cardiovascular Surgery
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research presented at Heart Failure 2017 and the 4th World Congress on Acute Heart Failure, April 29-May 2 in Paris, France. The breakthrough came on the 50th anniversary of heart transplantation.
May 23, 2017Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
Case Study | Cardiovascular Information Systems (CVIS)
Located along Mississippi’s Gulf Coast, Memorial Hospital at Gulfport is a nonprofit, 445-bed facility originally ...
May 23, 2017
Videos | Pacemakers
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospital ...
May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation ...
May 23, 2017Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023News | Heart Failure
Serelaxin failed to meet the primary endpoints of the phase 3 RELAX-AHF-2 trial, according to late-breaking results presented at Heart Failure 2017 and the 4th World Congress on Acute Heart Failure, April 29-May 2 in Paris, France.
May 22, 2017
News | Mobile Devices
May 22, 2017 — Consumers are being warned about the accuracy of heart rate apps after a study found huge variability ...
May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a definitive license agreement for the continued Phase III development and worldwide commercialization of flurpiridaz F-18. Flurpiridaz F-18 is an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent that may improve the diagnosis of coronary artery disease (CAD), the most common form of heart disease. The definitive agreement follows the signing of a term sheet previously announced in late February 2017.
May 22, 2017© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now